CClinicalTrials.gg
RecruitingNCT05511337Updated Dec 26, 2023

Gut Microbiota in Patients With Urolithiasis

An interventional study of Caloric restriction and control oxalate and citrate foods and Caloric restriction in Urolithiasis, sponsored by Hospital Regional de Alta Especialidad de la Península de Yucatán. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Hospital Regional de Alta Especialidad de la Península de Yucatán · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Urolithiasis (UL) is the presence of kidney stones in different compartments such as ureters, bladder and/or urethra. Based on its incidence and prevalence it is considered a public health problem worldwide. In Mexico, especially in Yucatan state, is considered an endemic area of UL with a prevalence of 5.5%. There are several risk factors associated with the development of UL, among which are genetics, age, sex, excess weight, diet, and gut microbiota. In the diet there is promoters and inhibitors of stone formation, such as oxalates and citrates respectively. The gut microbiota is the set of microorganisms that inhabit the gastrointestinal tract, which have been related to the regulation of metabolic processes such as production of short-chain fatty acids (SCFA), vitamin K synthesis, and stimulation of the immune response. However, alterations in the composition of the microbiota have been associated with the development of various pathologies including UL. Recent studies have shown that the intestinal microbiota of people with kidney stones have a lower diversity and a different bacterial composition compared with healthy people, suggesting that interactions in the gut-renal axis could have a direct effect on the development of UL. Furthermore, these modifications could modulate oxalate and citrate transporters. Dietary modifications may decrease the risk of UL formation through increased consumption of citrate-rich foods (>40 mEq per day) and decreased consumption of oxalate-rich foods (\< 40mg per day). It is known that dietary modifications can modulate the gut microbiota, however there is no evidence about the effect of a dietary intervention with oxalate and citrate control on the modulation of the microbiota in patients with UL. Thus, it is important to search for strategies to reduce UL, as well as the complications associated with them like chronic kidney disease. The main of the study is evaluate the effect of a dietary intervention with oxalate and citrate control on the composition and diversity of the intestinal microbiota of adults with UL.

Read the detailed description

The protocol will be carried out in the Hospital Regional de Alta Especialidad de la Península de Yucatán (HRAEPY). This is double-blind randomized clinical study will be carried out in adults with a diagnosis of UL. Participants with UL are randomized by into three groups for 28 days. Control group: Caloric restriction, restriction of 500 kilocalories from the usual diet, or Intervention A: Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (> 40 mEq per day), or Intervention B: Real-life intervention with control oxalate and citrate foods: decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (> 40 mEq per day) without restriction of kilocalories from the usual diet. Randomization was performed by balanced blocks of three cells, with the research randomizer randomization program, 60 sites were randomized, which 20 participants were divided into three groups. Randomization was carried out by a person outside the study.

At the beginning and at the end of the interventions, the following characteristics will be determined anthropometric measurements (weight, height, waist circumference, body mass index (BMI)) and blood pressure. A 24-h urine sample is requested to determine oxalates and citrates. A fasting blood sample of 8-10 hours will be requested for the determination of the concentration of creatinine, uric acid, calcium, phosphorus and sodium. A stool sample will also be requested for DNA extraction, which will be used for analysis of the composition and biodiversity of the intestinal microbiota. The person performing of measurements will be blinded to the group to which each participant belongs. Treatment will be given only through dietary counseling. Follow-up is done by telephone monitoring once a week through logbook and reminders. At the end of the study, the statistical analysis will be performed by a person who is blinded to the group to which the participants belong.

The sample size was calculated with the formula for comparison of two proportions, with a one-tailed significance of 0.05 and a power of 80%, with a change in alpha diversity in the intervention group of 57% and in the control group of 18%. The result was 16 patients per group, but a 20% loss was considered. Therefore, a total of 20 participants per group was considered.

02

Conditions studied

  • Urolithiasis
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects living in Merida, Yucatan
  • Female or male
  • Age between 18 and 60 years
  • Confirmed diagnosis of UL confirmed with ultrasound (≥5mm) and/or radiographs or who had expelled a stone in a time no longer than 7 days at the time of selection
  • BMI ≥ 25 and ≤ 39.9 kg/m2; no antibiotic intake (last 30 days)
  • No intake of probiotics, prebiotics or synbiotics (last 15 days)
  • No intake vitamin C supplements (last 15 days)
  • No intake calcium supplements (last 15 days)

Exclusion criteria

Exclusion criteria:

  • Previous medical diagnosis of chronic kidney disease
  • Serum creatinine >1.2 mg/dL
  • Glomerular filtration \<60 mL/min or 130 mL/min
  • Type 2 diabetes
  • Renal tubular acidosis
  • Pregnancy

Elimination criteria:

  • Not meeting 80% adherence to treatment
  • Antibiotic consumption during the intervention
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Control

    Caloric restriction

    Other: Caloric restriction

  • Experimental
    Intervention A

    Caloric restriction and control oxalate and citrate food

    Other: Caloric restriction and control oxalate and citrate foods

  • Experimental
    Intervention B

    Real-life intervention, control of oxalates and citrates without restriction of kilocalories.

    Other: Real-life intervention with control oxalate and citrate foods

Interventions

  • OtherCaloric restriction and control oxalate and citrate foods

    Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) for 28 days. The treatment will be given through an individualized meal plan.

  • OtherCaloric restriction

    Restriction of 500 kilocalories from the usual diet for 28 days. The treatment will be given through an individualized meal plan

  • OtherReal-life intervention with control oxalate and citrate foods

    Decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) without restriction in kilocalories from the usual diet for 28 days. Treatment will be given only through dietary counseling.

05

What researchers measure

Primary outcomes

  1. Relative abundance of gut microbiota

    Changes in relative abundance of phylum, gender and species of bacteria in gut microbiota

    Time frame: At the beginning of the study and after 28 days of intervention

Secondary outcomes

  1. Concentration of urinary citrate excretion

    Changes in concentration of citrate excretion in 24-hour urine

    Time frame: At the beginning of the study and after 28 days of intervention

  2. Concentration of urinary oxalate excretion

    Changes in concentration of oxalate excretion in 24-hour urine

    Time frame: At the beginning of the study and after 28 days of intervention

  3. Concentration of serum creatinine

    Changes in concentration of creatinine in serum

    Time frame: At the beginning of the study and after 28 days of intervention

  4. Concentration of serum calcium

    Changes in concentration of calcium in serum

    Time frame: At the beginning of the study and after 28 days of intervention

  5. Concentration of serum uric acid

    Changes in concentration of uric acid in serum

    Time frame: At the beginning of the study and after 28 days of intervention

  6. Concentration of serum phosphorus

    Changes in concentration of phosphorus in serum

    Time frame: At the beginning of the study and after 28 days of intervention

06

Study locations

1 of 1 sites recruiting
  • Azalia Avila Nava, PhD
    Mérida, Yucatán 97130, Mexico
    • Azalia A Nava, PhD · Contact
    Recruiting
07

References and documents

Publications

  • Areses Trapote R, Urbieta Garagorri MA, Ubetagoyena Arrieta M, Mingo Monge T, Arruebarrena Lizarraga D. [Evaluation of renal stone disease: metabolic study]. An Pediatr (Barc). 2004 Nov;61(5):418-27. doi: 10.1016/s1695-4033(04)78417-9. Spanish. PubMed 15530322 ↗
  • Medina-Escobedo M, Zaidi M, Real-de Leon E, Orozco-Rivadeneyra S. [Urolithiasis prevalence and risk factors in Yucatan, Mexico]. Salud Publica Mex. 2002 Nov-Dec;44(6):541-5. Spanish. PubMed 20383456 ↗
  • Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009 Summer;11(3):134-44. PubMed 19918339 ↗
  • Ticinesi A, Milani C, Guerra A, Allegri F, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Dodi R, Dall'Asta M, Del Rio D, Ventura M, Meschi T. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018 Dec;67(12):2097-2106. doi: 10.1136/gutjnl-2017-315734. Epub 2018 Apr 28. PubMed 29705728 ↗
  • Del Chierico F, Vernocchi P, Dallapiccola B, Putignani L. Mediterranean diet and health: food effects on gut microbiota and disease control. Int J Mol Sci. 2014 Jul 1;15(7):11678-99. doi: 10.3390/ijms150711678. PubMed 24987952 ↗
  • Stanislawski MA, Frank DN, Borengasser SJ, Ostendorf DM, Ir D, Jambal P, Bing K, Wayland L, Siebert JC, Bessesen DH, MacLean PS, Melanson EL, Catenacci VA. The Gut Microbiota during a Behavioral Weight Loss Intervention. Nutrients. 2021 Sep 18;13(9):3248. doi: 10.3390/nu13093248. PubMed 34579125 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT05511337
Lead sponsor
Hospital Regional de Alta Especialidad de la Península de Yucatán
Responsible party
Azalia Avila Nava, PhD (Principal Investigator, Hospital Regional de Alta Especialidad de la Península de Yucatán) — Principal investigator
First posted
Aug 23, 2022
Start date
Dec 15, 2022
Primary completion
Dec 2024 (estimated)
Completion
Aug 2025 (estimated)
Last update
Dec 26, 2023

Study contacts

Azalia Avila-Nava, PhD
Contact
zomi33@gmail.com
01 999 94 27600 ext. 54440

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion